What do systematic reviews say?

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

The review found no eligible studies for this question.

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Medication management vs usual care

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Very low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.98]
  1 study · 282 participants
  High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings ‐ initiation of penicillin prophylaxis vs placebo

Summary of findings ‐ initiation of penicillin prophylaxis may leads to lower incidence of S pneumoniae infection Isolated bacterial infection compared with placebo (low certainty).

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  OR 0.37 [0.16, 0.86]
  2 studies · 457 participants
  Low

Summary of findings ‐ withdrawal of penicillin prophylaxis vs continuation

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 400 participants
  Low

Summary of findings ‐ withdrawal of penicillin prophylaxis vs continuation

Summary of findings ‐ withdrawal of penicillin prophylaxis showed no clear difference in requirement of other courses of antibiotics compared with continuation (low certainty).

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  OR 0.94 [0.55, 1.61]
  1 study · 400 participants
  Low